Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2023-01-16 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于为子公司提供担保及申请银行授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 福安药业（集团）股份有限公司 regarding guarantees provided for its subsidiaries and applications for bank credit lines. It details the credit limits, banks involved, guarantee parties, financial data of the subsidiaries, and approvals from the board and independent directors. The content focuses on financing guarantees and credit facilities rather than financial results, management changes, or legal proceedings. The document length is 3705 characters, which is relatively short but contains substantive information about financing guarantees. This fits the category of Capital/Financing Update (CAP), as it updates on company financing activities and guarantees. It is not a full financial report, earnings release, or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2023-01-16 Chinese
独立董事关于第五届董事会第八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a specific board meeting matter regarding providing guarantees for a subsidiary's bank credit application. It references compliance with regulatory guidelines and company rules but does not contain financial statements or detailed financial data. The document is a formal opinion related to board/management decisions rather than a full report or announcement of voting results. It is not a general regulatory filing or a report publication announcement. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2023-01-16 Chinese
关于子公司收到醋酸奥曲肽注射液药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (707 characters) about a subsidiary receiving a drug registration certificate from the National Medical Products Administration. It contains no financial data, no detailed financial statements, or analysis. It is an official announcement regarding regulatory approval of a product, not a financial report or detailed management discussion. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it does not mention any report being published or attached. The content is regulatory in nature, informing investors about a regulatory milestone and associated risks. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2023-01-06 Chinese
关于参加重庆辖区上市公司2022年投资者网上集体接待日活动的公告
Regulatory Filings Classification · 90% confidence The document is an announcement about the company's participation in an investor online collective reception day event, where senior management will communicate with investors about governance, strategy, and business conditions. It does not contain financial statements, detailed financial data, or a report itself. The document is short (635 characters) and serves as a notice of an event rather than a report or transcript. Therefore, it fits best under Investor Presentation (IP) as it involves management presenting to investors, but since it is only an announcement of participation and not the presentation itself, it is more appropriate to classify it as Regulatory Filings (RNS) as a general regulatory announcement about investor relations activities.
2022-12-20 Chinese
关于收到碘海醇注射液药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (806 characters) from a company about receiving an approval notice from the National Medical Products Administration regarding a drug supplement application. It does not contain financial data, detailed financial results, or management discussion. It is an official announcement about regulatory approval of a pharmaceutical product, not a financial report or detailed investor presentation. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-12-06 Chinese
关于收到化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (743 characters) from a company about receiving an approval notice from the National Medical Products Administration for a chemical raw material drug listing application. It does not contain financial data, management discussion, or detailed report content. It is an official notification about regulatory approval related to product listing, not a financial report or management report. The document is an announcement of a regulatory event, fitting best under Regulatory Filings (RNS) as it does not match other more specific categories like capital updates, earnings, or governance.
2022-11-15 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.